SARS-CoV-2 Antibodies and Antigens

InVivo has developed a large set of reagents for COVID-19 research and industrial-scale manufacturing of highly sensitive in vitro diagnostics kits. Our portfolio comprises different recombinant versions of the SARS-CoV-2 Spike protein, that were transiently expressed in our high-yielding mammalian HEK cells. These include the full-length Spike protein, the two functional subunits S1 and S2, plus the S1 receptor-binding domain (RBD). The antigens display great activity and proper glycosylation and are suitable for the development of highly sensitive immunoassays. To cater to long-term demand of bulk quantities in the gram scale, InVivo offers recombinant Spike antigen production from stable CHO cell pools. The portfolio was recently expanded by several mutant Spike antigens of the recently discovered variants from UK, South Africa and Brazil. These antigens were produced via transient expression in our proprietary HEK system. Additionally, we offer the SARS-CoV-2 Nucleocapsid protein from bacterial expression systems for research use as well. For industry-scale manufacturing of SARS-CoV-2 detection kits (ELISA, Lateral Flow and more), InVivo provides different monoclonal antibodies from mouse hybridoma, which target the SARS-CoV-2 Spike or Nucleocapsid proteins, respectively. All Spike protein antibodies were validated by ELISA and demonstrate specificity for either the S1-subunit or the RBD region. Humanized chimeric recombinant antibodies targeting the Spike protein are still in development and will be available soon.

A) Schematic overview of the SARS-CoV-2 Spike (S) protein and its functional domains. The S protein plays a crucial role in the infection process and is therefore a great target for the development of diagnostic assays. It is comprised of two subunits: S1 and S2. The S1-subunit (aa 1-681) enables binding of the virion to the ACE2 receptor on the host cell membrane which initiates the infection. It contains an N-terminal signal peptide and the receptor-binding domain (RBD; aa 319-541) highlighted in grey. The S2-subunit (aa 685-1273) contains a C-terminal transmembrane domain (TMD) and an endodomain. It mediates the fusion of the virion with the cellular membranes. The process of membrane fusion depends on S protein cleavage (Furin cleavage site, aa 682-685) leading to the activation of the S protein during infection.

B) Schematic overview of the SARS-CoV-2 Nucleocapsid (N) protein and its functional domains. The SARS-CoV-2 Nucleocapsid (N) protein is the major structural component of the virion. It is involved in viral replication, assembly and immune regulation and plays key roles in the viral life cycle. Both, the N-terminal Domain (NTD, aa 48–175) and the C-terminal Domain (CTD, aa 247–364), are capable of binding to the viral positive-sense, single-stranded RNA (+ssRNA). The CTD is furthermore responsible for the dimerization of the N protein. In between NTD and CTD lies an intrinsically disorder region (IDR), which interacts with the viral matrix protein (M), thus forming a physical connection between RNA genome and envelope.

SARS-CoV-2 Pipeline – ANTIGENS

Product-ID	Description	Status
NP_HEK	Recombinant Nucleocapsid (N) protein (aa 1–419) with C-terminal deca-His-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 1-step purification via affinity chromatography (AC) to a purity of ≥90%. Product Information	Available
S1-RBD_CHO	Recombinant Spike protein receptor binding domain (aa 319-541) with C-terminal hexa-His-Tag, stably expressed in CHO cell pools. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
Soluble Spike_CHO	Recombinant soluble Spike protein (aa 14-1213) stably expressed in CHO cell pools. The soluble Spike contains a mutated polybasic/ furin cleavage site, and mutations K986P/V987P for stabilization of the trimer. The C-terminal TMD and endodomain were replaced by a thrombin cleavage site, a trimerization site and a C-terminal hexa-His-Tag. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD_HEK	Recombinant Spike protein receptor binding domain (aa 319-541) with C-terminal hexa-His-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-Subunit_HEK	Recombinant Spike protein S1-subunit (aa 14-681), transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-Subunit-Fc_HEK	Recombinant Spike protein S1-subunit (aa 14-681) with C-terminal Fc-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S2-Subunit-Fc_HEK	Recombinant Spike protein S2-subunit (aa 685-1213; excluding TMD and endodomain) with C-terminal Fc-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
Soluble Spike_HEK	Recombinant soluble Spike protein (aa 14-1213) transiently expressed in InVivo’s proprietary optimized HEK-INV cells. The soluble Spike contains a mutated polybasic/ furin cleavage site, and mutations K986P/V987P for stabilization of the trimer. The C-terminal TMD and endodomain were replaced by a thrombin cleavage site, a trimerization site and a C-terminal hexa-His-Tag. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available

SARS-CoV-2 Pipeline – MUTANT SPIKE ANTIGENS

Throughout the COVID-19 pandemic, several genetic variants of SARS-CoV-2 have emerged worldwide, which are classified as so-called variants of concern (VOC) or variants of interest (VOI). Amongst other things, there is evidence for an increased transmissibility of these virus variants and a significant reduction of neutralization through existing antibodies. Many mutations affect the Spike protein and its receptor binding domain (RBD).

To investigate the influence of these mutations on the effectiveness of SARS-CoV-2 diagnostics, InVivo offers a series of mutant Spike antigens that were transiently expressed in high yielding mammalian HEK cells. These include several RBD mutants, such as the Alpha variant (B.1.1.7) with or without additional immune-escape mutation E484K, the Beta variant (B.1.351), the Gamma variant (B.1.1.28.1 / P.1), the Delta variant (B.1.617.2) and the Kappa variant (B.1.617.1).

Furthermore, the full-length S-protein mutant of the Alpha variant is available, as well as a stabilized hexa-Pro mutant,

All antigens were produced under serum-free conditions in high-yielding HEK cells (InVEST). The antigens include a C-terminal poly-histidine-tag and were purified via affinity chromatography (AC) and preparative SEC (for polishing) to obtain purity > 90%. The protein activity was validated through an in-house SARS-CoV-2 IgG ELISA.

Product-ID	Description	Status
Spike-Alpha (B.1.1.7)_HEK	Spike protein of emerging Alpha B.1.1.7 SARS-CoV-2 VOC-202012/01 (HV 69-70 del, Y144 del, N501Y, A570D, P681H, T716I, S982A, D1118H). Protein design and manufacturing process is based on InVivo’s “Soluble Spike” protein (aa 14-1213). The C-terminal TMD and endodomain were replaced by a TEV cleavage site, a trimerization site and a C-terminal deca-His-Tag. 2-step purification via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Alpha (B.1.1.7)_HEK	RBD of emerging Alpha B.1.1.7 SARS-CoV-2 VOC-202012/01; mutation N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Alpha (B.1.1.7)+E484K_HEK	RBD of emerging Alpha B.1.1.7 SARS-CoV-2 variant with additional immune-escape mutation E484K, N501Y VOC-202102/02. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Beta (B.1.351)_HEK	RBD of emerging Beta B.1.351 SARS-CoV-2 variant; mutations K417N, E484K, N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Gamma (P.1)_HEK	RBD of emerging Gamma P.1 SARS-CoV-2 variant; mutations K417T, E484K, N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Kappa (B.1.617.1)_HEK	RBD of emerging Kappa B.1.617.1 SARS-CoV-2 Variant of Interest VOC-21APR-01; mutations L452R, E484Q. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Delta (B.1.617.2)_HEK	RBD of emerging Delta (B.1.617.2) SARS-CoV-2 variant; mutations L452R, T478K. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD_Delta-Plus (AY.1/AY.2)_HEK	RBD of emerging Delta-Plus (AY.1/AY.2) SARS-CoV-2 variant; mutations L452R, T478K, K417N. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Lambda (C.37)_HEK	RBD of Lambda C.37 SARS-CoV-2 variant; mutations L452Q, F490S. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Eta (B.1.525)_HEK	RBD of Eta (B.1.525) SARS-CoV-2 variant; mutation E484K. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Mu (B.1.621)_HEK	RBD of Mu B.1.621 SARS-CoV-2 variant; mutations R346K, E484K, N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
S1-RBD-Omicron (BA.2)_HEK	RBD of Omicron (sublineage BA.2) SARS-CoV-2 variant with mutations: G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y and Y505H.BA.2 is the second most common Omicron sublineage. InVivo’s construct contains 16 mutations, which all occur with a frequency of >75% (based on public data from https://outbreak.info/). Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via affinity chromatography (AC) and preparative SEC (polishing) to a purity ≥ 90%. Product Information	Available
NP-Omicron (BA.1)_HEK	Nucleocapsid (N) protein of Omicron BA.1 SARS-CoV-2 variant with mutations P13L, Δ31-33, R203K, G204R. Protein design and manufacturing process is based on InVivo’s N protein (aa 1–419) with C-terminal deca-His-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 1-step purification via affinity chromatography (AC) to a purity of ≥90%. Product Information	Available

SARS-CoV-2 Pipeline – ANTIBODIES

For industry-scale manufacturing of SARS-CoV-2 detection kits (ELISA, Lateral Flow and more), InVivo provides a set of different monoclonal IgG antibodies from mouse hybridoma, which selectively target either the SARS-CoV-2 Spike protein (S) or the Nucleocapsid protein (NP). The antibodies were produced from hybridoma under serum-free conditions and purified via Protein-A affinity chromatography to a purity > 90%. All antibodies were validated by ELISA and some of them are specifically recommended for Sandwich-ELISAs or neutralization assays. In addition to monoclonal antibodies from mouse hybridoma, InVivo also offers recombinant, chimeric antibodies containing mouse variable domains (V_L+V_H) fused with human IgG1 (C_H) and kappa (C_L) constant domains. The recombinant antibodies were produced under serum-free conditions in high-yielding HEK cells and purified via Protein-A affinity chromatography to obtain purity > 90%.

Description	Product-ID	Specificity	Host	Clonality	Isoptype	Subclass	Application
Anti-Spike (RBD) Antibody Product Information	AK3398	RBD	Mouse	Monoclonal	IgG	mIgG1κ	ELISA Immunoblot
Anti-Spike (RBD) Antibody Product Information	AK3399	RBD	Mouse	Monoclonal	IgG	mIgG2bκ	ELISA Sandwich-ELISA AK3426+AK3399 Immunoblot
Anti-Spike (RBD) Antibody Product Information	AK3400	RBD	Mouse	Monoclonal	IgG	mIgG2bκ	ELISA Immunoblot
Anti-Spike (RBD) Antibody Product Information	AK3401	RBD	Mouse	Monoclonal	IgG	mIgG2bκ	ELISA Immunoblot
Anti-Spike (RBD) Antibody Product Information	AK3402	RBD	Mouse	Monoclonal	IgG	mIgG2bκ	ELISA Immunoblot
Anti-Spike (RBD) Antibody Product Information	AK3403	RBD	Mouse	Monoclonal	IgG	mIgG1κ	ELISA Sandwich-ELISA AK3427+AK3403 Immunoblot
Anti-Spike (RBD) Antibody Product Information	AK3404	RBD	Mouse	Monoclonal	IgG	mIgG1κ	ELISA Sandwich-ELISA AK3404+AK3429 AK3404+AK3423 Immunoblot
Anti-Spike (S1) Antibody Product Information	AK3422	S1	Mouse	Monoclonal	IgG	mIgG2aκ	ELISA Sandwich-ELISA AK3426+AK3422 AK3427+AK3422 Immunoblot
Anti-Spike (S1) Antibody Product Information	AK3423	S1	Mouse	Monoclonal	IgG	mIgG1κ	ELISA Sandwich-ELISA AK3404+AK3423 Immunoblot
Anti-Spike (S1) Antibody Product Information	AK3424	S1	Mouse	Monoclonal	IgG	mIgG2bκ	ELISA Immunoblot
Anti-Spike (RBD) Antibody Product Information	AK3426	RBD	Mouse	Monoclonal	IgG	mIgG1κ	ELISA Sandwich-ELISA AK3426+AK3399 Immunoblot
Anti-Spike (RBD) Antibody Product Information	AK3427	RBD	Mouse	Monoclonal	IgG	mIgG1κ	ELISA Sandwich-ELISA AK3427+AK3403 AK3427+AK3422 Immunoblot
Anti-Spike (S1) Antibody Product Information	AK3429	S1	Mouse	Monoclonal	IgG	mIgG1κ	ELISA Sandwich-ELISA AK3404-AK3429 Immunoblot
Anti-NP Antibody Product Information	AK3432	NP	Mouse	Monoclonal	IgG	mIgG1	ELISA Sandwich-ELISA
Anti-NP Antibody Product Information	AK3433.1	NP	Mouse	Monoclonal	IgG	mIgG2b	ELISA Sandwich-ELISA
Anti-NP Antibody Product Information	AK3454	NP	Mouse	Monoclonal	IgG	mIgG1κ	ELISA
Anti-NP Antibody Product Information	AK3455	NP	Mouse	Monoclonal	IgG	mIgG2aκ	ELISA
Anti-NP Antibody Product Information	AK3456	NP	Mouse	Monoclonal	IgG	mIgG2aκ	ELISA
Anti-NP Antibody Product Information	AK3457	NP	Mouse	Monoclonal	IgG	mIgG2aκ	ELISA
Anti-NP Antibody Product Information	AK3458	NP	Mouse	Monoclonal	IgG	mIgG1κ	ELISA
Anti-NP Antibody Product Information	AK3459	NP	Mouse	Monoclonal	IgG	mIgG1κ	ELISA
Anti-Spike (RBD) rec Antibody Product Information	RP_SZ_824	RBD	Mammalian	NA	Human IgG	hIgG1κ	ELISA Immunoblot
Anti-Spike (S1) rec Antibody Product Information	RP_SZ_827	S1	Mammalian	NA	Human IgG	hIgG1κ	ELISA Immunoblot
Anti-Spike (RBD) recombinant chimeric IgA Antibody Product Information	RP_SZ_859	RBD	Mammalian	NA	Human IgA	hIgA1κ	ELISA Immunoblot
Anti-Spike (S1) recombinant chimeric IgA Antibody Product Information	RP_SZ_860	S1	Mammalian	NA	Human IgA	hIgA1κ	ELISA Immunoblot
Anti-Spike (RBD) recombinant chimeric IgA Antibody with J-chain (JC) Product Information	RP_SZ_861	RBD	Mammalian	NA	Human IgA + JC	hIgA1κ	ELISA Immunoblot
Anti-Spike (S1) recombinant chimeric IgA Antibody with J-chain (JC) Product Information	RP_SZ_862	S1	Mammalian	NA	Human IgA + JC	hIgA1κ	ELISA Immunoblot

SARS-CoV-2 Pipeline – Recombinant ACE2 Proteins

Angiotensin-converting enzyme 2 (ACE2) is a zinc-containing metalloenzyme, which regulates blood pressure through proteolysis of Angiotensin II. ACE2 also serves as an entry point into the cells for different coronaviruses, including SARS-CoV-2. Using the Spike protein RBD which protrudes from the viral membrane surface, the virus binds to the peptidase domain (PD) of ACE2, thereby initiating the infection process. The collectrin-like domain (CLD) is responsible for the homo-dimerization of ACE2. InVivo offers a recombinant form of the full-length ACE2 ectodomain, as well as the ACE2-PD produced in high-yielding HEK cells.

Product-ID	Description	Status
ACE2_HEK	Recombinant ACE2 (aa 1-740) with native signal peptide and the entire extracellular domain (including PD and CLD). The protein contains a C-terminal hexa-His-tag and is produced under serum-free conditions in HEK cells. Purification via Affinity Chromatography (AC) to a purity ≥ 90%. Product Information	Available
ACE2-PD_HEK	Recombinant ACE2 (1–615) with native signal peptide and PD (excluding CLD). The protein contains a C-terminal hexa-His-tag and is produced under serum-free conditions in HEK cells. Purification via Affinity Chromatography (AC) to a purity ≥ 90%. Product Information	Available

Product-ID

Description

Status

ACE2_HEK

Recombinant ACE2 (aa 1-740) with native signal peptide and the entire extracellular domain (including PD and CLD). The protein contains a C-terminal hexa-His-tag and is produced under serum-free conditions in HEK cells. Purification via Affinity Chromatography (AC) to a purity ≥ 90%.

Product Information

Available

ACE2-PD_HEK

Recombinant ACE2 (1–615) with native signal peptide and PD (excluding CLD). The protein contains a C-terminal hexa-His-tag and is produced under serum-free conditions in HEK cells. Purification via Affinity Chromatography (AC) to a purity ≥ 90%.

Product Information

Available

InVivo also offers custom solutions for the production of other Coronavirus antigens. If none of the products mentioned above are of your interest, please reach out to us and learn about production capacities and timelines for your protein of choice.

Contact Us

Invivo Biotech Services

Neuendorfstr. 24a
16761 Hennigsdorf
Germany

First Name (Required)

Last Name (Required)

Email Address (Required)

Phone

Company (Required)

Enquiry (Required)

How did you hear about us?

email_subscribe_callback email_subscribe_callback I would like to have a callback by my specified contact details I would like to receive latest news and special offers from InVivo

GDPR GDPR I hereby confirm that I have read and agree with the privacy policy.

12 + 7 =